The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

Start Date10 Oct 2024

Sponsor / Collaborator

Eli Lilly & Co.

NCT06169982

/ CompletedPhase 1

A Phase 1, Open-Label, Multiple-Dose Study to Investigate Steady-State Pharmacokinetics and Pharmacodynamics During a Euglycemic Clamp of LY3209590 in Participants With Type 2 Diabetes Mellitus

The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.

Start Date07 Dec 2023

Sponsor / Collaborator

Eli Lilly & Co.

NCT05914688

/ CompletedPhase 1

A Bioequivalence Study of Subcutaneous Injections of LY3209590 in Two Formulations in Healthy Participants

The main purpose of this study is to compare the two formulations of LY3209590 in healthy participants. Study participants will be administered each formulation at separate study visits. Blood samples will be taken to compare how the body handles study drugs. The information about any adverse effects experienced will be collected and the tolerability of LY3209590 will also be evaluated.
Screening is required within 28 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 184 days including screening.

Start Date26 Jun 2023

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Basal Insulin Fc(Eli Lilly & Co.)

100 Translational Medicine associated with Basal Insulin Fc(Eli Lilly & Co.)

100 Patents (Medical) associated with Basal Insulin Fc(Eli Lilly & Co.)

115

Literatures (Medical) associated with Basal Insulin Fc(Eli Lilly & Co.)

01 Oct 2025·JOURNAL OF DIABETES AND ITS COMPLICATIONS

Degludec insulin versus efsitora insulin in diabetes mellitus management: A systematic review and meta-analysis

Article

Author: Gallo Ruelas, Mariano ; Flávio-Reis, Victor Hugo Palhares ; Queiroz, Ivo ; Barbosa, Lucas Mendes ; de Oliveira, Helen Michaela ; Zamora, Fernanda Valeriano ; Cavalcante, Deivyd Vieira Silva

PURPOSE:

To compare the efficacy and safety of next-generation basal insulin efsitora versus insulin degludec in managing type 1 and type 2 diabetes.

METHODS:

We systematically searched PubMed, Embase, and CENTRAL databases until October 2024. This study followed PRISMA guidelines. Statistical analyses were performed using R version 4.4.1. The risk of bias was assessed using the RoB2 tool, and the quality of evidence was evaluated using the GRADE approach. This study was registered in PROSPERO under protocol CRD42024597806.

RESULTS:

Six randomized controlled trials involving 2590 patients were included in the analysis. Of these, 1376 (53.13 %) received efsitora insulin. No significant differences were observed between efsitora and degludec in glycemic efficacy outcomes, including HbA1c reduction, fasting blood glucose, weight change, and proportion of patients achieving HbA1c <7 %. Regarding safety outcomes, most endpoints, such as adverse events, injection site reactions, hypersensitivity, severe hypoglycemia, and mortality, were comparable between groups, with no significant subgroup effects. However, subgroup analysis revealed a lower incidence of nocturnal hypoglycemia with efsitora in patients with type 2 diabetes, and a higher rate of serious adverse events in patients with type 1 diabetes, suggesting potential population-specific differences in safety profiles.

CONCLUSION:

Efsitora and degludec insulins show similar overall efficacy and safety in the management of diabetes. However, subgroup analyses indicate that patient-specific factors, such as diabetes type, may influence the risk of certain adverse events. These findings support the importance of individualized insulin selection based on patient characteristics and risk profiles.

01 Aug 2025·EUROPEAN JOURNAL OF NEUROSCIENCE

Efficacies of Bifidobacterium and Fecal Microbiota Transplantation in Rats With Chronic Hepatic Encephalopathy Assessed by [¹⁸F]PBR146 Imaging of Neuroinflammation

Article

Author: Yang, Gui Fen ; Jiang, Jing Zhou ; Wu, Shi Yao ; Zhang, Jun ; Luo, Song ; Zhang, Long Jiang ; Lu, Guang Ming ; Kong, Xiang

ABSTRACT:

Neuroinflammation significantly contributes to hepatic encephalopathy (HE). The radiotracer [18F]PBR146 is used for in vivo imaging of neuroinflammation. Promising treatments like Bifidobacterium (BIF) and fecal microbiota transplantation (FMT) are being explored for HE. This study evaluated and compared the efficacies of BIF and FMT in reducing neuroinflammation in chronic HE rats induced by bile duct ligation (BDL) using [18F]PBR146 micro‐PET/CT imaging. Thirty rats were divided into four groups: (1) Sham‐operated rats received normal saline (Sham + NS group), (2) BDL rats treated with NS (BDL + NS group), (3) BDL rats administered with BIF (BDL + BIF group), and (4) BDL rats administered with FMT (BDL + FMT group). Following the establishment of the chronic HE model, we conducted sequential behavioral assessments, collected fecal samples, and performed micro‐PET/CT scans. Data analysis included average %ID/g values across the whole brain and specific regions, alongside biochemical and pathological evaluations. No significant differences in behavioral results or levels of IL‐1β, IL‐6, IL‐10, and TNF‐α were found among the groups. While there was no significant difference in global brain uptake values of [18F]PBR146 among the four groups (p = 0.053), regional analyses showed significant discrepancies in areas such as the bilateral accumbens and retrosplenial cortex. The Sham + NS group was enriched with Parasutterella, Streptococcus, and Anaeroplasma, the BDL + FMT group had Enterococcus, Aestuariispira, Lactobacillus, Pseudomonas, and Globicatella, while the BDL + BIF group contained Enterorhabdus. Results indicated that BIF inhibited neuroinflammation in BDL rats, whereas FMT showed no positive effects, possibly due to dysbiosis. Notably, [18F]PBR146 could effectively and noninvasively monitor the efficacies of gut‐targeted treatments in chronic HE models.

24 Jul 2025·NEW ENGLAND JOURNAL OF MEDICINE

Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy

Article

Author: Connery, Lisa ; Bailey, Timothy ; Desouza, Cyrus ; Miller, Eden ; Rosenstock, Julio ; Carr, Molly C. ; Child, Christopher J. ; Knights, Alastair ; Leohr, Jennifer ; Wang, Qianqian

BACKGROUND:

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa (efsitora), a once-weekly basal insulin, may provide a benefit in adults with type 2 diabetes who have not received previous insulin therapy.

METHODS:

We conducted a 52-week, phase 3, open-label, treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin therapy. Participants were randomly assigned in a 1:1 ratio to receive once-weekly efsitora or once-daily insulin glargine U100 (glargine). Treatment with efsitora was initiated as a single dose of 100 U administered once weekly, with dose adjustments made every 4 weeks, as needed, at fixed doses of 150, 250, and 400 U to achieve fasting blood glucose levels of 80 to 130 mg per deciliter. Doses of glargine were adjusted weekly or more often according to a standard algorithm to reach the same glycemic goals. The primary end point, tested for noninferiority (noninferiority margin, 0.4 percentage points), was the change from baseline in the glycated hemoglobin level at 52 weeks.

RESULTS:

A total of 795 participants underwent randomization. The mean glycated hemoglobin level decreased from 8.20% at baseline to 7.05% at week 52 with efsitora (least-squares mean change, -1.19 percentage points) and from 8.28% to 7.08% with glargine (least-squares mean change, -1.16 percentage points); the estimated between-group difference of -0.03 percentage points (95% confidence interval [CI], -0.18 to 0.12) confirmed the noninferiority of efsitora to glargine. Superiority was not shown (P = 0.68). The rate of combined clinically significant hypoglycemia (glucose level, <54 mg per deciliter) or severe hypoglycemia (level 3; requiring assistance for treatment) was lower with efsitora than with glargine (0.50 events per participant-year of exposure with efsitora vs. 0.88 with glargine; estimated rate ratio, 0.57 [95% CI, 0.39 to 0.84]). At week 52, the mean total weekly insulin dose was 289.1 U per week with efsitora and 332.8 U per week with glargine (estimated between-group difference, -43.7 U per week; 95% CI, -62.4 to -25.0); the median number of dose adjustments needed was 2 with efsitora and 8 with glargine.

CONCLUSIONS:

In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora, administered in a fixed-dose regimen, was noninferior to once-daily glargine in reducing glycated hemoglobin levels. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT05662332.).

News (Medical) associated with Basal Insulin Fc(Eli Lilly & Co.)

24 Jun 2025

·pmlive.com

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

Eli Lilly has shared promising phase 3 results for its once-weekly insulin candidate efsitora alfa in adults with type 2 diabetes (T2D). All three studies met their primary endpoint of non-inferior A1C reduction compared to daily basal insulin, according to data presented at this year’s American Diabetes Association Scientific Sessions. More than 4.3 million people in the UK have diabetes, with T2D accounting for around 90% of all cases. Current treatment options focus on disease management and include diet and exercise, diabetes medications and insulin therapy. It is hoped that an insulin option specifically designed for once-weekly subcutaneous administration could improve adherence rates and quality of life for patients with the chronic condition. QWINT-1, which evaluated efsitora alfa in patients using insulin for the first time, showed that Lilly’s candidate reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52. In the trial, efsitora was titrated across four fixed doses at four-week intervals, as needed for blood glucose control. In QWINT-3 and QWINT-4, which enrolled patients who had previously used daily basal insulin, and those who had previously used daily basal insulin and mealtime insulin, respectively, efsitora was given using traditional insulin dosing, with adjustments based on each patient’s glucose level. At week 26 in QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec. At the same time point in QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine. Efsitora also demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for T2D across all three studies. Jeff Emmick, senior vice president of product development at Lilly, said: “These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach.” Lilly said it is planning to submit global regulatory applications for efsitora as a treatment for adults with T2D by the end of this year. “We look forward to working with regulatory agencies to bring this innovation to patients around the world,” Emmick said.

Clinical ResultPhase 3

23 Jun 2025

·www.fiercepharma.com

Lilly eyes global approval filings as once-weekly insulin candidate takes clinical victory lap

Eli Lilly says it plans to take its efsitora data package to global regulatory agencies by the end of this year. With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa.Lilly on Sunday provided a comprehensive look at positive results from its QWINT-1, QWINT-3 and QWINT-4 studies, which assessed efsitora in Type 2 diabetes patients using insulin for the first time, those who previously used daily basal insulin and those who previously used daily basal insulin and mealtime insulin, respectively.Efsitora—which would allow diabetes patients to cut back on more than 300 insulin injections per year if approved—helped patients achieve noninferior A1C (blood sugar) reduction versus daily basal insulin in all three studies, helping the clutch of trials meet their primary endpoints, Lilly said.With those winning results in hand, Lilly says it plans to take its efsitora data package to global regulatory agencies by the end of this year. Overall, Lilly has unveiled positive readouts from five different trials in the QWINT program, which kicked off in 2022.The momentum behind efsitora comes as Lilly’s chief metabolic medicine rival Novo Nordisk has struggled to win clearance for its own once-weekly insulin in the U.S. That said, Novo’s drug, known commercially as Awiqli, already boasts approvals in territories like Europe, Canada, Japan and Australia. Breaking down the results, efsitora helped reduce patients’ A1C by 1.31% versus 1.27% for insulin glargine at the QWINT-1 study’s 52-week mark. In QWINT-3, efsitora reduced A1C by 0.86% at Week 26 and in QWINT-4 by 1.07% over the same time frame, compared to 0.75% for insulin degludec and 1.07% for insulin glargine, respectively.Lilly also unveiled results from several key secondary endpoints in QWINT-3 and 4. In the former trial, efsitora patients’ glucose levels were in range 62.8% of the time during the four weeks leading up to Week 26 of the study, compared to 61.3% of the time for those on insulin degludec.In QWINT-4, meanwhile, efsitora helped 39.5% of patients achieve an A1C less than 7% at Week 26 without nocturnal hypoglycemia, compared to 36.6% of patients receiving insulin glargine.For QWINT-1, Lilly says it titrated efsitora to four fixed doses at four-week intervals, as needed for blood glucose control. In QWINT-3 and 4, efsitora was given via traditional insulin dosing with adjustments according to each patient’s glucose level, the company explained.Efsitora’s safety in the three studies was on par with insulin glargine and insulin degludec, which are among the most commonly used daily basal insulins, Lilly noted in its release.In the QWINT-1 study, patients on efsitora experienced roughly 40% fewer hypoglycemic events—when a person’s blood sugar drops too low—compared to insulin glargine, Lilly pointed out.Meanwhile, at the QWINT-1 study’s 52-week mark, the estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure was 0.50 with efsitora versus 0.88 with insulin glargine. For QWINT-3, those results clocked in at 0.84 with efsitora versus 0.74 with insulin degludec at 78 weeks, while the QWINT-4 results came in at 6.6 with efsitora versus 5.9 with insulin glargine at 26 weeks."Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," Jeff Emmick, M.D., Ph.D., Lilly’s senior vice president of product development, said in a statement. "These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach”Across the QWINT program, Lilly has looked at efsitora’s performance in more than 3,000 Type 2 diabetes patients. QWINT-1 enrolled 795 participants versus 986 for QWINT-3 and 730 for QWINT-4.Lilly presented the latest trio of readouts over the weekend at the 85th American Diabetes Association Scientific Sessions in Chicago. The results from QWINT-1 were also published in The New England Journal of Medicine, while data from QWINT-3 and 4 have made their way into The Lancet, according to Lilly.The detailed look at QWINT-1, 3 and 4 follows a succession of positive readouts from the program since last May, when Lilly first revealed that the QWINT-2 and 4 studies had met their A1C noninferiority endpoints. QWINT-2 was specifically designed to assess whether the use of GLP-1 medicines for diabetes like Mounjaro or Novo’s Ozempic could weigh on efsitora’s efficacy.Lilly is betting big on efsitora’s potential to both improve treatment for patients already using daily insulin and encourage new patients to start using the medication.“Imagine 313 fewer injections per year,” Paul Owens, VP of global brand development for insulins and glucagon at Lilly, said of the drug’s promise in an interview with Fierce Biotech last year. “We believe it has the potential to really improve adherence … and for some, the innovation of a simple, once-weekly approach to dosing could really mean the difference between starting the treatment and not.”Diabetes patients have been grappling with daily insulin dosing for nearly a century, and those repetitive injections in response to blood glucose tests can become a “huge burden” for people living with the disease, Owens said at the time.Though Novo Nordisk beat Lilly to the punch launching its weekly insulin product Awiqli overseas, Lilly now appears poised to take the lead in the U.S. Last July, the FDA rejected Novo’s application for the product, which is also known as insulin icodec. Novo credited the rejection to “requests related to the manufacturing process and the type 1 diabetes indication.” At the time, Novo cautioned that it didn’t expect to resolve the issue by the end of 2024.The snub followed an unfavorable vote from an FDA advisory committee, which largely revolved around questions about icodec’s potential to cause low blood sugar.Ultimately, seven of 11 panelists agreed that the data Novo presented were not sufficient to conclude that the benefits of icodec outweighed the risks for adults with Type 1 diabetes.

Clinical Result

23 Jun 2025

·pharma.economictimes.indiatimes.com

Lilly’s once-weekly insulin matches daily doses in efficacy across multiple trials

New Delhi: Eli Lilly ’s once-weekly type 2 diabetes insulin, efsitora alfa , has shown efficacy and safety results comparable to daily insulin across multiple Phase 3 trials . Announcing results from the three Phase 3 trials — QWINT-1, QWINT-3, and QWINT-4 — the company said: “In each trial, efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin.” The late-stage studies evaluated the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes, across different treatment histories: first-time insulin users, prior daily basal insulin users, and users of both daily basal and mealtime insulin. Across the three studies, the investigational candidate reported greater A1C reduction compared to insulin glargine (at both 52 and 26 weeks) and degludec (at 26 weeks), along with 40 per cent fewer hypoglycemic events versus glargine. In the QWINT-1 trial, efsitora was titrated to four fixed doses at four-week intervals, while in the other two trials, dosing was adjusted using traditional insulin titration based on each patient's glucose levels. Complete results from the studies were presented at the ADA 85th Scientific Sessions 2025. Simultaneously, results from QWINT-1 — the first fixed-dose study of its kind — were published in The New England Journal of Medicine, while QWINT-3 and QWINT-4 results appeared in The Lancet. “Once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year. These results reinforce the potential to reduce the overall burden of insulin therapy through a simplified treatment approach,” said Jeff Emmick, Senior Vice President of Product Development, Eli Lilly. Lilly plans to submit efsitora for approval for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year, the company said in a release. Efsitora alfa combines a novel single-chain variant of insulin with a human IgG2 Fc domain, and is designed to provide more stable glucose levels with less variability throughout the week. Currently, Danish drugmaker Novo Nordisk has a once-weekly basal insulin — insulin icodec — marketed under the brand name Awiqli. By Online Bureau ,

Clinical ResultPhase 3Drug Approval

100 Deals associated with Basal Insulin Fc(Eli Lilly & Co.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Phase 3	United States	Eli Lilly & Co.	12 Aug 2022
Diabetes Mellitus, Type 1	Phase 3	Japan	Eli Lilly & Co.	12 Aug 2022
Diabetes Mellitus, Type 1	Phase 3	Argentina	Eli Lilly & Co.	12 Aug 2022
Diabetes Mellitus, Type 1	Phase 3	Poland	Eli Lilly & Co.	12 Aug 2022
Diabetes Mellitus, Type 1	Phase 3	Slovakia	Eli Lilly & Co.	12 Aug 2022
Diabetes Mellitus, Type 1	Phase 3	Taiwan Province	Eli Lilly & Co.	12 Aug 2022
Diabetes Mellitus, Type 2	Phase 3	United States	Eli Lilly & Co.	08 Mar 2022
Diabetes Mellitus, Type 2	Phase 3	Japan	Eli Lilly & Co.	08 Mar 2022
Diabetes Mellitus, Type 2	Phase 3	Argentina	Eli Lilly & Co.	08 Mar 2022
Diabetes Mellitus, Type 2	Phase 3	Hungary	Eli Lilly & Co.	08 Mar 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05662332 (QWINT-1, CTgov)	Phase 3	Diabetes Mellitus, Type 2	795	Insulin Efsitora Alfa (Insulin Efsitora Alfa)	kxjozoibvx = mbdcdsbegm nvgzspidji (qiqtpkpxsf, zirsgcforg - wolxtxvkni) View more	-	06 Aug 2025
				Insulin Glargine (Insulin Glargine)	kxjozoibvx = icbsbuuiec nvgzspidji (qiqtpkpxsf, fxgjkvbtpw - lofrpzisjm) View more
NCT05463744 (QWINT-5, CTgov)	Phase 3	Diabetes Mellitus, Type 1	692	Insulin Efsitora Alfa (500 U/mL Insulin Efsitora Alfa)	jmldagrsgp(vvbnaypmvi) = wjwclhkxgk mkadnliprt (tmsdqlcufq, 0.0469) View more	-	24 Jun 2025
				Insulin Degludec (100 U/mL Insulin Degludec)	jmldagrsgp(vvbnaypmvi) = coqwnooesd mkadnliprt (tmsdqlcufq, 0.0463) View more
NCT05275400 (QWINT-3, CTgov)	Phase 3	Diabetes Mellitus, Type 2	986	Insulin Efsitora Alfa (500 U/mL - Insulin Efsitora)	mxgmjlahow(bgaodmsffd) = cumfkcjxjo nfoxluntdf (uvqndorchr, 0.0302) View more	-	03 Jun 2025
				Insulin Degludec (100 U/mL - Insulin Degludec)	mxgmjlahow(bgaodmsffd) = bkgwkjpdpk nfoxluntdf (uvqndorchr, 0.0424) View more
NCT05362058 (Qwint-2, CTgov)	Phase 3	Diabetes Mellitus, Type 2	928	Insulin Efsitora Alfa (500 U/mL - Insulin Efsitora Alfa)	cgollxnoqs(mtizgxvnqr) = eynltmgusw gwqlermzwm (uqiwwqfgeq, 0.0470) View more	-	16 May 2025
				Insulin Degludec (100 U/mL - Insulin Degludec)	cgollxnoqs(mtizgxvnqr) = dxgbmuzlbg gwqlermzwm (uqiwwqfgeq, 0.0473) View more
NCT05462756 (QWINT-4, CTgov)	Phase 3	Diabetes Mellitus, Type 2	730	Insulin Efsitora Alfa+Insulin Lispro (U100) (500 U/mL - Insulin Efsitora)	nnfyaojlrp(kfihqikvbs) = snjfcgarvs fdhxjtnjzq (fqxvwjnlbo, 0.0463) View more	-	27 Apr 2025
				Insulin Glargine+Insulin Lispro (U100) (100 U/mL - Insulin Glargine)	nnfyaojlrp(kfihqikvbs) = ibqobsddun fdhxjtnjzq (fqxvwjnlbo, 0.0463) View more
NCT05463744 (QWINT-5, Company_Website) Manual	Phase 3	Diabetes Mellitus, Type 1	692	Insulin efsitora alfa	xifqxdalxt(vkyrssihfl) = hpnidddbcy mbfhxrfasd (yumlafaqdd ) Met View more	Non-inferior	10 Sep 2024
				Insulin degludec	xifqxdalxt(vkyrssihfl) = btsqmozopb mbfhxrfasd (yumlafaqdd ) Met View more
NCT05662332 (QWINT-1, NEWS 1 \| NEWS 2) Manual	Phase 3	Diabetes Mellitus, Type 2	-	Efsitora alfa	rbqmejmldz(vljbhcwics) = fspfxpsayp otwqzxfjrt (nraoqpqqvg ) Met View more	Non-inferior	09 Sep 2024
				Insulin glargine	rbqmejmldz(vljbhcwics) = kvyrdqhjvy otwqzxfjrt (nraoqpqqvg ) Met View more
NCT05275400 (QWINT-3, NEWS \| PRNewswire \| Company_Website \| Lancet) Manual	Phase 3	Diabetes Mellitus, Type 2	986	Efsitora Alfa	xnpvccdzau(ahvpgccjsn) = mbuxpjuhqi falhvzpcuu (ashdqaoaes ) Met View more	Non-inferior	05 Sep 2024
				Insulin degludec	xnpvccdzau(ahvpgccjsn) = infsriuotv falhvzpcuu (ashdqaoaes ) Met View more
NCT05462756 (QWINT-4, Biospace \| PRNewswire \| Company_Website \| Lancet) Manual	Phase 3	Diabetes Mellitus, Type 2	730	Efsitora	jbtmmbqbjr(vofzkllapr) = rcoizbmgrd gttvptcyru (agissfyuvm ) View more	Positive	16 May 2024
				Glargine	jbtmmbqbjr(vofzkllapr) = jxbjixqgui gttvptcyru (agissfyuvm ) View more
NCT05362058 (Qwint-2, Biospace) Manual	Phase 3	Diabetes Mellitus, Type 2	928	Efsitora alfa (Efsitora)	nofkyucxhb(aaiybnpvau) = zsehrgsocl uokwnpdpmz (jkfauqoioi ) Met View more	Non-inferior	16 May 2024
				Degludec (Tresiba)	nofkyucxhb(aaiybnpvau) = rmtpdnoxdg uokwnpdpmz (jkfauqoioi ) Met View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis